Body mass index influence interferon-beta treatment response in multiple sclerosis

Journal of Neuroimmunology

Volumn 288, Issue , 2015, Pages 92-97

  Kvistad, Silje Stokke ^a   Myhr, Kjell Morten ^a,b   Holmøy, Trygve ^c,d   Šaltyte Benth, Jurate ^c,d   Wergeland, Stig ^a   Beiske, Antonie G ^e   Bjerve, Kristian S ^f,g   Hovdal, Harald ^f   Lilleås, Finn ^h   Midgard, Rune ^g,i   Pedersen, Tom ^j   Bakke, Søren J ^k   Michelsen, Annika E ^d,k   Aukrust, Pål ^d,k   Ueland, Thor ^d,k,l   Sagen, Jørn V ^a,b   Torkildsen, Øivind ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Multiple Sclerosis Centre Hakadal   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h Curato Oslo   (Norway)

ⁱ Hospital of Molde   (Norway)

^j Unilabs   (France)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY OF TROMSØ   (Norway)

more..

Author keywords

Body mass index (BMI); Interferon beta treatment; MRI disease activity; Multiple sclerosis; No evidence of disease activity; Treatment response

Indexed keywords

25 HYDROXYVITAMIN D; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA INTERFERON; CXCL16 CHEMOKINE; GELATINASE B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MEMBRANE PROTEIN; OSTEOPONTIN; OSTEOPROTEGERIN; PENTRAXIN 3; PLACEBO; SECONDARY LYMPHOID TISSUE CHEMOKINE; SECRETED FRIZZLED RELATED PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NO EVIDENCE OF DISEASE ACTIVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADOLESCENT; BRAIN; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; BRAIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBESITY; YOUNG ADULT;

EID: 84945573317     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.09.008     Document Type: Article

References (35)

1. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol. 2007, 61:504-513.
2. Cambil-Martin J., Galiano-Castillo N., Munoz-Hellin E., Diaz-Rodriguez L., Laguarta-Val S., Fernandez-De-Las-Penas C., Arroyo-Morales M. Influence of body mass index on psychological and functional outcomes in patients with multiple sclerosis: a cross-sectional study. Nutr. Neurosci. 2014.
3. Cao H. Adipocytokines in obesity and metabolic disease. J. Endocrinol. 2014, 220:T47-T59.
4. Clanet M., Radue E.W., Kappos L., Hartung H.P., Hohlfeld R., Sandberg-Wollheim M., Kooijmans-Coutinho M.F., Tsao E.C., Sandrock A.W., European I.-A.D.-C.S.I. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59:1507-1517.
5. Hedstrom A.K., Olsson T., Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 2012, 18:1334-1336.
6. Holmoy T., Loken-Amsrud K.I., Bakke S.J., Beiske A.G., Bjerve K.S., Hovdal H., Lilleas F., Midgard R., Pedersen T., Saltyte Benth J., Torkildsen O., Wergeland S., Myhr K.M., Michelsen A.E., Aukrust P., Ueland T. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLoS One 2013, 8.
7. Kalincik T., Spelman T., Trojano M., Duquette P., Izquierdo G., Grammond P., Lugaresi A., Hupperts R., Cristiano E., Van Pesch V., Grand'maison F., La Spitaleri D., Rio M.E., Flechter S., Oreja-Guevara C., Giuliani G., Savino A., Amato M.P., Petersen T., Fernandez-Bolanos R., Bergamaschi R., Iuliano G., Boz C., Lechner-Scott J., Deri N., Gray O., Verheul F., Fiol M., Barnett M., Van Munster E., Santiago V., Moore F., Slee M., Saladino M.L., Alroughani R., Shaw C., Kasa K., Petkovska-Boskova T., Den Braber-Moerland L., Chapman J., Skromne E., Herbert J., Poehlau D., Needham M., Bacile E.A., Arruda W.O., Paine M., Singhal B., Vucic S., Cabrera-Gomez J.A., Butzkueven H., Group M.S.S. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013, 8.
8. Kappos L., Weinshenker B., Pozzilli C., Thompson A.J., Dahlke F., Beckmann K., Polman C., Mcfarland H., EUROPEAN INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS TRIAL STEERING, C., INDEPENDENT ADVISORY, B., NORTH AMERICAN INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS TRIAL STEERING, C., INDEPENDENT ADVISORY, B. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004, 63:1779-1787.
9. Konradsen S., Ag H., Lindberg F., Hexeberg S., Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur. J. Nutr. 2008, 47:87-91.
10. Langer-Gould A., Brara S.M., Beaber B.E., Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013, 80:548-552.
11. Li D.K., Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann. Neurol. 1999, 46:197-206.
12. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
13. Marrie R.A., Horwitz R.I., Cutter G., Tyry T., Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol. Scand. 2011, 124:135-141.
14. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., Dayer J.M. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?. J. Clin. Endocrinol. Metab. 2002, 87:1184-1188.
15. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., Brochet B., Canron M.H., Franconi J.M., Boiziau C., Petry K.G. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 2011, 17:2-15.
16. Munger K.L., Chitnis T., Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009, 73:1543-1550.
17. Munger K.L., Bentzen J., Laursen B., Stenager E., Koch-Henriksen N., Sorensen T.I., Baker J.L. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult. Scler. 2013, 19:1323-1329.
18. Nicoletti F., Patti F., Dimarco R., Zaccone P., Nicoletti A., Meroni P., Reggio A. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 1996, 8:395-400.
19. Nortvedt M.W., Riise T., Maeland J.G. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol. Sci. 2005, 26:334-339.
20. O'connor P., Filippi M., Arnason B., Comi G., Cook S., Goodin D., Hartung H.P., Jeffery D., Kap Pos L., Boateng F., Filippov V., Groth M., Knap V., Kraus C., Sandbrink R., Pohl C., Bogumil T., Group B.S., O'connor P., Filippi M., Arnason B., Cook S., Goodin D., Hartung H.P., Kap L., Jeffery D., Comi G. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009, 8:889-897.
21. Oliveira S.R., Simao A.N., Kallaur A.P., De Almeida E.R., Morimoto H.K., Lopes J., Dichi I., Kaimen-Maciel D.R., Reiche E.M. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition 2014, 30:268-273.
22. Overs S., Hughes C.M., Haselkorn J.K., Turner A.P. Modifiable comorbidities and disability in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2012, 12:610-617.
23. Panitch H., Miller A., Paty D., Weinshenker B., NORTH AMERICAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE, M.S. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795.
24. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res. Clin. Pract. 2005, 69:29-35.
25. Rotstein D.L., Healy B.C., Malik M.T., Chitnis T., Weiner H.L. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015, 72:152-158.
26. Sawcer S., Franklin R.J., Ban M. Multiple sclerosis genetics. Lancet Neurol. 2014, 13:700-709.
27. Shimada Y., Asanuma Y.F., Yokota K., Yoshida Y., Kajiyama H., Sato K., Akiyama Y., Mimura T. Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus. Mod. Rheumatol. 2014, 24:78-85.
28. Taylor K.L., Hadgkiss E.J., Jelinek G.A., Weiland T.J., Pereira N.G., Marck C.H., Van Der Meer D.M. Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry 2014, 14:327.
29. Torkildsen O., Wergeland S., Bakke S., Beiske A.G., Bjerve K.S., Hovdal H., Midgard R., Lilleas F., Pedersen T., Bjornara B., Dalene F., Kleveland G., Schepel J., Olsen I.C., Myhr K.M. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 2012, 69:1044-1051.
30. Versini M., Jeandel P.Y., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun. Rev. 2014, 13:981-1000.
31. Voltz R., Hartmann M., Spuler S., Scheller A., Mai N., Hohlfeld R., Yousry T. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J. Neurol. Neurosurg. Psychiatry 1997, 62:200-201.
32. Wang H., Wang K., Wang C., Zhong X., Qiu W., Hu X. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult. Scler. 2013, 19:926-931.
33. Wesnes K., Riise T., Casetta I., Drulovic J., Granieri E., Holmoy T., Kampman M.T., Landtblom A.M., Lauer K., Lossius A., Magalhaes S., Pekmezovic T., Bjornevik K., Wolfson C., Pugliatti M., Myhr K.M. Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Mult. Scler. 2014.
34. Witasp A., Carrero J.J., Michaelsson K., Ahlstrom H., Kullberg J., Adamsson V., Riserus U., Larsson A., Helmersson-Karlqvist J., Lind L., Stenvinkel P., Arnlov J. Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity (Silver Spring) 2014, 22:1373-1379.
35. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 2000, 72:690-693.